Cerivastatin and reports of fatal rhabdomyolysis [6] (multiple letters)

New England Journal of Medicine

Volumn 346, Issue 7, 2002, Pages 539-540

  Staffa, Judy A ^a   Chang, Jennie ^a   Green, Lanh ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATALITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0037075262     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200202143460721     Document Type: Letter

References (4)

1. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
2. Rhode Island physicians' recognition and reporting of adverse drug reactions
3. Spontaneous reporting in the United States